Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments
Our novel HD-modeling framework estimates HD progression over a lifetime and the associated costs and QALYs. Our approach can be used for future cost-effectiveness models as positive DMT clinical trial evidence becomes available.
Authors
- Shahid M. Malik (ORCID: https://orcid.org/0009-0007-9274-999X)
- Talaha M Ali (ORCID: https://orcid.org/0000-0002-3079-7853)
- Jamie Hamilton (ORCID: https://orcid.org/0000-0002-8522-610X)
- Idaira Rodríguez Santana (ORCID: https://orcid.org/0000-0003-2022-3239)
- Jeffrey D. Long (ORCID: https://orcid.org/0000-0001-7181-9652)
- Sarah J. Tabrizi (ORCID: https://orcid.org/0000-0003-2716-2045)
- Daniel O. Claassen (ORCID: https://orcid.org/0000-0002-9853-4902)
- Gregory F. Guzauskas (ORCID: https://orcid.org/0000-0002-9095-1672)
- Astri Arnesen (ORCID: https://orcid.org/0000-0003-0148-592X)
- Lei Zhang (ORCID: https://orcid.org/0000-0003-2760-0025)
- Lorraine Munetsi
Institutions
- Huntington's Disease Association (GB)
- University College London (GB)
Publication Details
- Journal
- Neurology Clinical Practice
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1212/cpj.0000000000200340
- Citations
- 1
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.27